SOLIRIS (eculizumab): The first treatment specifically approved for PNH

PNH Registry

The PNH Registry

Developed to further the medical community's understanding and management of PNH

PNH RegistryThe PNH Registry is the first prospective, international, longitudinal research initiative and database on patients with PNH. The PNH Registry was created to

  • Enhance understanding of PNH to optimize patient outcomes
  • Encourage collaboration and scientific exchange
  • Generate data reports to enable evidence-based diagnostic and treatment decision-making

 

Sponsored by Alexion Pharmaceuticals and supported by an International Scientific Advisory Board, the PNH Registry aims to join together physicians and patients from around the world.

Next: About SOLIRIS®

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Patients should be vaccinated with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS. Revaccinate according to current medical guidelines for vaccine use.

Patients should be monitored closely for early signs of meningococcal infections and evaluated immediately if infection is suspected, and treated with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.